Pauls Stradins Clinical University Hospital Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01951235
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pauls Stradins Clinical University Hospital | P. Stradins Clinical University Hospital | P. Stradins University Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

sitagliptin (januvia) (1 trial)

Drugs in Phase 2 Trials (1)

imeglimin (Twymeeg) (1 trial)

Drugs in Other Trials (2)

calcifediol (1 trial)

ergocalciferol (drisdol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Disease Progression (Phase 4)

Glucose Intolerance (Phase 4)

Myocardial Ischemia (Phase 4)

Prediabetic State (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4